Samsung Epis Holdings
Samsung Epis Holdings Co., Ltd., operating as Samsung Bioepis, is a South Korea-based biopharmaceutical enterprise focused on the development and commercialization of biosimilar therapeutics. The company engineers biosimilar formulations targeting immunology, oncology, ophthalmology, hematology, and endocrinology therapeutic fields. Principal revenue drivers consist of commercial sales of approved biosimilar drugs, milestone licensing payments from global marketing partners, and contract development income. Samsung Bioepis serves hospital systems, specialty clinics, retail pharmacies, and clinical healthcare providers across North America, Europe, and Asia-Pacific. The enterprise holds a leading international position as an established developer and manufacturer of complex biosimilars. Samsung Epis Holdings Co., Ltd. is headquartered in Incheon, South Korea, operating as a core biopharmaceutical subsidiary within the Samsung Group.
10 of the funds FundTelligence covers report a position in Samsung Epis Holdings.
- Legal name
- Samsung Epis Holdings Co Ltd
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 10
Funds holding Samsung Epis Holdings
- Handelsbanken Asia Tema — Handelsbanken · 0.04 % (full portfolio disclosed, August 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.02 % (full portfolio disclosed, June 2026)
- Storebrand Emerging Markets — Storebrand · 0.01 % (full portfolio disclosed, October 2026)
- SEB Emerging Markets Exposure — SEB · 0.01 % (full portfolio disclosed, June 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.01 % (full portfolio disclosed, October 2026)
- Storebrand Emerging Markets Plus — Storebrand · 0.01 % (full portfolio disclosed, October 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.0 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 10 funds holding it.